A Randomized Controlled Clinical Trial of the GLP-1 Agonist ROSE-010 in Appetite Reduction

被引：0
作者：
Kenny, Enda
Mansson, Maria
Samuelson, Per
Hellstrom, Per
机构：
来源：
OBESITY | 2024年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Poster-361
引用
收藏
页码：198 / 198
页数：1
相关论文
共 50 条
  • [41] Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo- controlled study
    Harrison, Stephen A.
    Browne, Sarah K.
    Suschak, John J.
    Tomah, Shaheen
    Gutierrez, Julio A.
    Yang, Jay
    Roberts, M. Scot
    Harris, M. Scott
    JOURNAL OF HEPATOLOGY, 2025, 82 (01) : 7 - 17
  • [42] Serum bile acids and GLP-1 decrease following telemetric induced weight loss: results of a randomized controlled trial
    Biemann, Ronald
    Penner, Marina
    Borucki, Katrin
    Westphal, Sabine
    Luley, Claus
    Roenicke, Raik
    Biemann, Kathleen
    Weikert, Cornelia
    Lux, Anke
    Goncharenko, Nikolai
    Marschall, Hanns-Ulrich
    Schneider, Jochen G.
    Isermann, Berend
    SCIENTIFIC REPORTS, 2016, 6
  • [43] Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials
    Yasmin Luz Lima de Mesquita
    Izabela Pera Calvi
    Isabela Reis Marques
    Sara Almeida Cruz
    Eduardo Messias Hirano Padrao
    Pedro Emanuel de Paula Carvalho
    Caroliny Hellen Azevedo da Silva
    Rhanderson Cardoso
    Filipe Azevedo Moura
    Vladimir Vitalievich Rafalskiy
    International Journal of Obesity, 2023, 47 : 883 - 892
  • [44] Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials
    de Mesquita, Yasmin Luz Lima
    Calvi, Izabela Pera
    Marques, Isabela Reis
    Cruz, Sara Almeida
    Padrao, Eduardo Messias Hirano
    Carvalho, Pedro Emanuel de Paula
    da Silva, Caroliny Hellen Azevedo
    Cardoso, Rhanderson
    Moura, Filipe Azevedo
    Rafalskiy, Vladimir Vitalievich
    INTERNATIONAL JOURNAL OF OBESITY, 2023, 47 (10) : 883 - 892
  • [45] The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
    Drucker, Daniel J.
    DIABETES, 2018, 67 (09) : 1710 - 1719
  • [46] Effects of GLP-1 Receptor Agonist on Chronic Axonal Damage, Neurodegeneration, and Cognitive Function in Relapsing-remitting MS (MSGLP): Exploratory, Open Label, Randomized Controlled Trial
    Imrich, Richard
    Penesova, Adela
    Vlcek, Miroslav
    Radikova, Zofia
    Havranova, Andrea
    Siarnik, Pavol
    Hardonova, Miroslava
    Kollar, Branislav
    Turcani, Peter
    NEUROTHERAPEUTICS, 2024, 21 (04)
  • [47] A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan
    Brady, E. M.
    Davies, M. J.
    Gray, L. J.
    Saeed, M. A.
    Smith, D.
    Hanif, W.
    Khunti, K.
    DIABETES OBESITY & METABOLISM, 2014, 16 (06) : 527 - 536
  • [48] Factors associated with A1C reduction with GLP-1 agonist or SGLT-2 inhibitor use
    Davis, Hanifah
    Heilmann, Rachel
    Milchak, Jessica
    Delate, Thomas
    FAMILY PRACTICE, 2021, 38 (05) : 623 - 629
  • [49] The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials
    Aldawsari, Malikah
    Almadani, Fatima A.
    Almuhammadi, Nujud
    Algabsani, Sarah
    Alamro, Yara
    Aldhwayan, Madhawi
    DIABETES METABOLIC SYNDROME AND OBESITY, 2023, 16 : 575 - 595
  • [50] GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy
    Roumane, Ahlima
    Mcilroy, George D.
    Sommer, Nadine
    Han, Weiping
    Heisler, Lora K.
    Rochford, Justin J.
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
12345